Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Ryukaikon Confab Held after 17 Month Hiatus, COVID-19 Impact on Drug Distribution Discussed
Members of the “Ryukaikon” council for the improvement of the drug distribution environment discussed the impact of COVID-19 on downstream transactions between wholesalers and healthcare providers on November 24 at its first meeting since June 2019. They agreed to make…
To read the full story
Related Article
- JPMA Concerned about COVID-19 Pandemic’s Impact on Efforts to Improve Distribution
November 26, 2020
- Drug Price Negotiations in 1st Half Delayed by COVID-19 Impact: JPWA Survey
November 25, 2020
- Single Product, Single Price Trade Ratio in H1 FY2020 Virtually Flat: MHLW
November 25, 2020
- Ryukaikon Confab Finally Set for November 24; Can Japan Improve Drug Distribution Environment Again?
November 4, 2020
REGULATORY
- Pharma Seeks Inflation-Liked Price Hikes, Freeze on Patent-Period Cuts for 2027 Revision
August 27, 2026
- Kisunla Braced for NHI Price Cut after CEA; Leqembi Method to Apply
August 27, 2026
- Xcopri, Leqembi SC Now in Line for Japan Approval with Panel Backing
August 27, 2026
- MHLW Seeks Record 36.6 Trillion Yen for FY2027, Puts AI in Focus
August 27, 2026
- Generic Re-Pricing Relief Reaches Just 1 in 10 Unprofitable Products: JGA
August 27, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…